In glioblastoma studies, CAR T cells targeting IL-13Rα2 were modified to over-express transgenic IL-15 and demonstrated that IL-15 cytokine secretion was T cell activation dependent and resulted in improved CAR T cell persistence in vitro. This evidence concerns the gene IL13RA2 and glioblastoma.